Evaluating GnRH Agonist Injections Before Frozen Embryo Transfer for Women With Endometriosis andor Adenomyosis

What this Trial Is About

This research aims to evaluate whether adding one or two doses of a GnRH agonist injection Decapeptyl 3mg before frozen embryo transfer can improve pregnancy rates in women with endometriosis andor adenomyosis. These conditions involve the presence of uterine tissue outside the normal lining or within the muscle layer, leading to pain, infertility, and lower chances of embryo implantation due to inflammation. The study compares the effects of the GnRH agonist combined with the usual hormone replacement therapy against hormone replacement therapy alone. Participants receive either standard hormonal replacement therapy with estrogens and progestins or that therapy plus one or two injections of the GnRH agonist about one month before embryo transfer. The study groups are randomly assigned, and no masking is used. The main focus is on the frozen embryo transfer procedure supported by these hormonal treatments, assessing how the additional GnRH agonist influences outcomes. During the study, participants will be monitored for pregnancy success through ultrasound three months after the embryo transfer, measuring clinical pregnancy rates as the primary outcome. Secondary outcomes include implantation success, miscarriage rates, and any side effects related to the GnRH agonist treatment over 15 months. Women aged 18 to 36 with documented endometriosis or adenomyosis and planning frozen embryo transfer are included, with regular follow-ups to assess the treatments effects and safety.

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis